NASDAQ:MDGLMadrigal Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Madrigal Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $104.88 +1.78 (+1.73 %) (As of 08/7/2020 04:00 PM ET) Add Compare Share Today's Range$102.77Now: $104.88▼$107.0150-Day Range$99.78MA: $107.36▼$112.2552-Week Range$56.82Now: $104.88▼$127.25Volume5,839 shsAverage Volume93,530 shsMarket Capitalization$1.62 billionP/E RatioN/ADividend YieldN/ABeta1.22 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia. It is also developing MGL-3745, a THR-ß-selective small molecule that is in preclinical trials. The company has research, development, and commercialization agreement with Hoffmann-La Roche to develop, use, sell, offer for sale, and import various licensed products. Madrigal Pharmaceuticals, Inc. was founded in 2011 and is headquartered in West Conshohocken, Pennsylvania.Read More Beat the Market (BTM) Rank™ 4.4 Analyst's Opinion Consensus RatingMadrigal Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 10 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $168.40, Madrigal Pharmaceuticals has a potential upside of 60.6% from its current price of $104.88.Amount of Analyst CoverageMadrigal Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.8 Community Rank Outperform VotesMadrigal Pharmaceuticals has received 394 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMadrigal Pharmaceuticals has received 302 “underperform” votes. (Add your “underperform” vote.)Community SentimentMadrigal Pharmaceuticals has received 56.61% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Madrigal Pharmaceuticals and other stocks. Vote “Outperform” if you believe MDGL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MDGL will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMadrigal Pharmaceuticals does not currently pay a dividend.Dividend GrowthMadrigal Pharmaceuticals does not have a long track record of dividend growth. Previous Next 2.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Madrigal Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders41.89% of the stock of Madrigal Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions70.94% of the stock of Madrigal Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Madrigal Pharmaceuticals are expected to decrease in the coming year, from ($10.04) to ($11.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Madrigal Pharmaceuticals is -12.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Madrigal Pharmaceuticals is -12.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMadrigal Pharmaceuticals has a P/B Ratio of 3.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.84 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:MDGL Previous Symbol CUSIP87162T20 CIK1157601 Webwww.madrigalpharma.com Phone267-824-2827Debt Debt-to-Equity RatioN/A Current Ratio15.93 Quick Ratio15.93Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$27.00 per share Price / Book3.88Profitability EPS (Most Recent Fiscal Year)($5.45) Net Income$-83,950,000.00 Net MarginsN/A Return on Equity-32.44% Return on Assets-30.77%Miscellaneous Employees17 Outstanding Shares15,430,000Market Cap$1.62 billion Next Earnings Date11/4/2020 (Estimated) OptionableOptionable $104.88 +1.78 (+1.73 %) (As of 08/7/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive MDGL News and Ratings via Email Sign-up to receive the latest news and ratings for MDGL and its competitors with MarketBeat's FREE daily newsletter. Madrigal Pharmaceuticals (NASDAQ:MDGL) Frequently Asked Questions How has Madrigal Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Madrigal Pharmaceuticals' stock was trading at $81.06 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MDGL shares have increased by 29.4% and is now trading at $104.88. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Madrigal Pharmaceuticals? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Madrigal Pharmaceuticals. When is Madrigal Pharmaceuticals' next earnings date? Madrigal Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for Madrigal Pharmaceuticals. How were Madrigal Pharmaceuticals' earnings last quarter? Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) released its earnings results on Thursday, August, 6th. The biopharmaceutical company reported ($3.18) earnings per share for the quarter, missing the Zacks' consensus estimate of ($2.43) by $0.75. During the same period last year, the firm earned ($1.28) EPS. View Madrigal Pharmaceuticals' earnings history. What price target have analysts set for MDGL? 12 Wall Street analysts have issued 12 month price objectives for Madrigal Pharmaceuticals' shares. Their forecasts range from $114.00 to $208.00. On average, they anticipate Madrigal Pharmaceuticals' share price to reach $168.40 in the next year. This suggests a possible upside of 60.6% from the stock's current price. View analysts' price targets for Madrigal Pharmaceuticals. Has Madrigal Pharmaceuticals been receiving favorable news coverage? News coverage about MDGL stock has been trending very positive on Saturday, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Madrigal Pharmaceuticals earned a media sentiment score of 4.0 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news about Madrigal Pharmaceuticals. Who are some of Madrigal Pharmaceuticals' key competitors? Some companies that are related to Madrigal Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Novavax (NVAX). View all competitors. What other stocks do shareholders of Madrigal Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Madrigal Pharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Viking Therapeutics (VKTX), Advaxis (ADXS), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Crispr Therapeutics (CRSP), Amarin (AMRN), Intercept Pharmaceuticals (ICPT), Sarepta Therapeutics (SRPT) and Consolidated Water (CWCO). Who are Madrigal Pharmaceuticals' key executives? Madrigal Pharmaceuticals' management team includes the following people: Dr. Paul A. Friedman, Chairman & CEO (Age 76)Dr. Rebecca A. Taub, Founder, Exec. VP of R&D, Chief Medical Officer and Director (Age 67)Mr. Marc R. Schneebaum, Sr. VP & CFO (Age 65)Mr. Thomas W. Hare, Sr. VP of Clinical Management What is Madrigal Pharmaceuticals' stock symbol? Madrigal Pharmaceuticals trades on the NASDAQ under the ticker symbol "MDGL." Who are Madrigal Pharmaceuticals' major shareholders? Madrigal Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Jennison Associates LLC (1.15%), Candriam Luxembourg S.C.A. (0.66%), Frontier Capital Management Co. LLC (0.47%), Swiss National Bank (0.15%), Alps Advisors Inc. (0.14%) and Mutual of America Capital Management LLC (0.13%). Company insiders that own Madrigal Pharmaceuticals stock include Bay City Capital Llc, Fred B Craves and Paul A Friedman. View institutional ownership trends for Madrigal Pharmaceuticals. Which institutional investors are selling Madrigal Pharmaceuticals stock? MDGL stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Frontier Capital Management Co. LLC, UBS Group AG, Alps Advisors Inc., SG Americas Securities LLC, Trexquant Investment LP, Mutual of America Capital Management LLC, and Virtus ETF Advisers LLC. View insider buying and selling activity for Madrigal Pharmaceuticals. Which institutional investors are buying Madrigal Pharmaceuticals stock? MDGL stock was acquired by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Rafferty Asset Management LLC, WINTON GROUP Ltd, Swiss National Bank, Nisa Investment Advisors LLC, Principal Financial Group Inc., Leap Investments LP, and Arizona State Retirement System. Company insiders that have bought Madrigal Pharmaceuticals stock in the last two years include Fred B Craves, and Paul A Friedman. View insider buying and selling activity for Madrigal Pharmaceuticals. How do I buy shares of Madrigal Pharmaceuticals? Shares of MDGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Madrigal Pharmaceuticals' stock price today? One share of MDGL stock can currently be purchased for approximately $104.88. How big of a company is Madrigal Pharmaceuticals? Madrigal Pharmaceuticals has a market capitalization of $1.62 billion. The biopharmaceutical company earns $-83,950,000.00 in net income (profit) each year or ($5.45) on an earnings per share basis. Madrigal Pharmaceuticals employs 17 workers across the globe. What is Madrigal Pharmaceuticals' official website? The official website for Madrigal Pharmaceuticals is www.madrigalpharma.com. How can I contact Madrigal Pharmaceuticals? Madrigal Pharmaceuticals' mailing address is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. The biopharmaceutical company can be reached via phone at 267-824-2827 or via email at [email protected] This page was last updated on 8/8/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
